I hereby cartify that . . correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents, Washington D.C. 2013 on 2015 Commissioner.

Washington, D.C. 20231 on 246 Sept 2000

Lillian S. Glenn

6 Rec'd PCT/PTO 29 SEP 2000

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK

In re Application of: Thomas F. Tedder

Group Art U

0520g

Serial No.: 09/555,349

Filed: May 26, 2000

Date of Signature

Examiner:

•

Docket No.: 180/95 PCT/US

For: ANTIBODY PRODUCTION METHODS RELATED TO DISRUPTION OF

PERIPHERAL TOLERANCE IN B LYMPHOCYTES

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents BOX PCT Washington, D.C. 20231

Sir

Applicants respectfully note that there is an error on the formal Filing Receipt. Namely, the applicant should be listed as a "Small Entity" as per the attached executed Small Entity Statement. Applicant has also enclosed a copy of the return postcard, Express Mail certificate and a copy of the filing receipt with the addition marked in red ink.

Applicant respectfully requests a corrected filing receipt be issued for the subject patent application.

Although it is believed that no fee is due in this matter, the Commissioner is hereby authorized to charge any deficiency in payment associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 09/26/2000

By:

Arles A. Taylor, Jr. Registration No. 39,395

Suite 1400 University Tower 3100 Tower Boulevard Durham, North Carolina 27707 Telephone: (919) 493-8000 Facsimile: (919) 419-0383

AAT/Isa

180/95 PCT/US





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office


Address: ASSISTANT SECRETARY AND

COMMISSIONER OF PATENT AND TRADEMARKS

Washington, D.C. 20231

	APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
,	09/555 349	08/01/2000	1632	1035	180/95/PCT/LI	5	28	

ARLES A TAYLOR JR JENKINS & WILSON UNIVERSITY TOWER 3100 TOWER BOULEVARD SUITE 1400 DURHAM, NC 27707



Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

THOMAS F. TEDDER, DURHAM, NC;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/US98/25253 11/25/1998 WHICH CLAIMS BENEFIT OF 60/065,975 11/28/1997

Foreign A	pplications
-----------	-------------

If Required, Foreign Filing License Granted 08/14/2000

* SMALL ENTITY **

MOCKET DATE: NA	
ASSIGNED BY: LSb	
DOCKETED BY: LS-	
DATE: 8/2/0	

Title

ANTIBODY PRODUCTION METHODS RELATING TO DISRUPTION OF PERIPHERAL TOLERANCE IN B LYMPHO-CYTES

Preliminary Class

435

Data entry by: ORDENEZ, MARTA

Team: OIPE

Date: 08/14/2000

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the
 Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along
 with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



Practitioner's Docket No. 180/95 PCT/US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Tedder, Thomas F.

Application No.:

09/555,349

Filed on:

May 26, 2000

Title:

ANTIBODY PRODUCTION METHODS RELATED TO DISRUPTION OF

PERIPHERAL TOLERANCE IN B LYMPHOCYTES

STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(b)--NONPROFIT ORGANIZATION

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Nonprofit:

DUKE UNIVERSITY

Address of Nonprofit:

230 North Building

Research Drive

Durham, North Carolina 27708

TYPE OF NONPROFIT ORGANIZATION

University or Other Institution of Higher Education.

I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization, as defined in 37 CFR 1.9(e), for purposes of paying reduced fees to the United States Patent and Trademark Office under Sections 41(a) and (b) of Title 35, United States Code, with regard to the invention described in the application identified above.

I hereby state that rights under contract or law have been conveyed to, and remain with, the nonprofit organization, with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. 1.9(c), if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e)

No such person, concern, or organization exists. I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Robert L. Taber Vice Chancellor/Director Duke University 230 North Building, Research Drive Durham, North Carolina 27708 UNITED STATES OF AMERICA

SIGNATURE W

Date 7/11/00